Compugen Says COM701 (Anti-PVRIG) Mediates Anti-Tumor Activity In Patients Typically Not Responding To Immunotherapy
Portfolio Pulse from Benzinga Newsdesk
Compugen has announced that its drug COM701 (Anti-PVRIG) has shown anti-tumor activity in patients who typically do not respond to immunotherapy. This could potentially expand the patient population for immunotherapy treatments.
November 06, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Compugen's COM701 has shown promising results in patients not typically responsive to immunotherapy. This could potentially increase the market for their product.
The news of COM701's effectiveness in a new patient population could potentially increase the market for Compugen's product. This could lead to increased revenues and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100